DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
45 hedge funds and large institutions have $6.44M invested in DMK Pharmaceuticals Corporation Common Stock in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 6 closing their positions.
1,862% more call options, than puts
Call options by funds: $510K | Put options by funds: $26K
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
2% less funds holding
Funds holding: 46 → 45 (-1)
13% less capital invested
Capital invested by funds: $7.38M → $6.44M (-$934K)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$41.8K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$32.1K |
| 3 |
HF
HRT Financial
New York
|
+$12.1K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$8.61K |
| 5 |
Jane Street
New York
|
+$7.77K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$77.6K |
| 2 |
JP Morgan Chase
New York
|
-$25K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$21.4K |
| 4 |
Principal Financial Group
Des Moines,
Iowa
|
-$10K |
| 5 |
Goldman Sachs
New York
|
-$7K |
DMK Hedge Fund Activity: Q2 2022 in Review
45 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q2 2022, worth a combined $6.44M — down 13% from $7.38M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of DMK and 5 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 8 added.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $41.8K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $77.6K sold.
- 45 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q2 2022, down from 46 in Q1 2022.
- Funds reported $6.44M of DMK Pharmaceuticals Corporation Common Stock stock for Q2 2022, down 13% quarter-over-quarter.
- 5 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q2 2022 and 6 closed out, a net change of -1 holder.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q2 2022 was Two Sigma Securities, an estimated $41.8K added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q2 2022 was Susquehanna International Group, an estimated $77.6K sold.
Based on aggregated 13F filings for Q2 2022.